Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

Entrectinib is a potent small-molecule tyrosine kinase inhibitor that targets oncogenic rearrangements in NTRK, ROS1, and ALK. The consolidated results of 2 Phase I trials demonstrated activity in tyrosine kinase inhibitor-naïve patients along with substantial intracranial activity. In ROS1-rearrang...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dazhi, Offin, Michael, Harnicar, Stephen, Li, Bob T, Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055893/
https://www.ncbi.nlm.nih.gov/pubmed/30050303
http://dx.doi.org/10.2147/TCRM.S147381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055893/
https://www.ncbi.nlm.nih.gov/pubmed/30050303
http://dx.doi.org/10.2147/TCRM.S147381

Ejemplares similares